AfyaIndex — Drug Search

01 Risk first

Safety essentials

The information most likely to change a prescribing or dispensing decision.

Contraindications

Hypersensitivity to the active substance or excipients.
Additional absolute contraindications are indication- and product-specific — consult SmPC.

Precautions

WARNINGS For topical ophthalmic use only.
Not for injection.
This preparation may cause CNS disturbances which may be dangerous in pediatric patients.
The possibility of psychotic reactions and behavioral disturbances due to hypersensitivity to anticholinergic drugs should be considered.
Mydriatics may produce a transient elevation of intraocular pressure.
Remove contact lenses before using.

02 Point of care

Dosing matrix

Population and organ-function guidance, shown together for faster comparison.

Adult

DOSAGE AND ADMINISTRATION For refraction, instill one or two drops of 1% solution in the eye(s), repeated in five minutes. If patient is not seen within 20 to 30 minutes, an additional drop may be instilled to prolong mydriatic effect. For examination of fundus, instill one or two drops of 0.5% solution 15 or 20 minutes prior to examination. Individuals with heavily pigmented irides may require higher strength or more doses. Mydriasis will reverse spontaneously with time, typically in 4 to 8 hours. However, in some cases, complete recovery may take up to 24 hours. To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Paediatric

See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.

Renal

Review renal impairment dosing; many agents need CrCl/eGFR adjustment.

CrCl 0–120: Confirm renal dosing in product SmPC / primary label.

Hepatic

Review hepatic impairment dosing; monitor LFTs if agent is hepatically cleared or hepatotoxic.

03 Clinical use

Use, effects & interactions

Indications

INDICATIONS AND USAGE For mydriasis and cycloplegia for diagnostic procedures.
Clinical selection for Tropicamide should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
Class context: Anticholinergic [EPC].
Confirm site-specific dose, duration and monitoring before prescribing.

Adverse effects

ADVERSE REACTIONS Ocular: Transient stinging, blurred vision, photophobia and superficial punctate keratitis have been reported with the use of tropicamide.
Increased intraocular pressure has been reported following the use of mydriatics.
Non-Ocular: Dryness of the mouth, tachycardia, headache, allergic reactions, nausea, vomiting, pallor, central nervous system disturbances and muscle rigidity have been reported with the use of tropicamide.
Psychotic reactions, behavioral disturbances, and vasomotor or cardio-respiratory collapse in children have been reported with the use of anticholinergic drugs.

Drug interactions

Open multi-drug checker ↗

Professional use: confirm indication, dose, duration, monitoring and patient counselling points against current Kenya STG / EML and the product SmPC.
Document allergy status and key interactions.

04 Pharmacology

Mechanism & disposition

A short acting antimuscarinics Mechanism is agent-specific.

A short acting antimuscarinics Mechanism i…At receptor, enzyme, ion channel, transpor…Confirm precise molecular mechanism in cur…

Read complete mechanism

A short acting antimuscarinics Mechanism is agent-specific. At receptor, enzyme, ion channel, transporter or microbial target level, the drug alters a physiological or pathological pathway to produce its therapeutic effect. Confirm precise molecular mechanism in current SmPC / pharmacology reference for this INN before high-stakes decisions.

Onset

Product-specific

Duration

Product-specific

Route

OPHTHALMIC

05 Special populations

Pregnancy, lactation & diet

Pregnancy

Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.

Lactation

Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.

06 Kenya market

Brands & loaded prices

From—

Median—

Listings0

Brand	Manufacturer	Pack	Observed price
No reviewed brand listings are linked yet.

07 Provenance

Sources & review state

Primary sourceLocal active-ingredient clinical extract; FDA drug label via OpenFDA/DailyMed; Professional class pharmacology (Therapeutic agent (verify pharmacological class))

Last reviewedNot recorded

EvidenceSource-linked

Open source document ↗

Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.